Cargando…

T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective

Cellular immunotherapeutic approaches such as chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) thus far have not met the high expectations. Therefore it is essential to better understand the molecular mechanisms of CLLinduced T-cell dysfunction. Even though a sign...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peters, Fleur S., Strefford, Jonathan C., Eldering, Eric, Kater, Arnon P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586819/ https://www.ncbi.nlm.nih.gov/pubmed/33691381 http://dx.doi.org/10.3324/haematol.2020.267914

Ejemplares similares

P593: T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Montironi, Chiara, et al.
Publicado: (2023)

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia
por: Montironi, Chiara, et al.
Publicado: (2023)

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
por: van Attekum, Martijn HA, et al.
Publicado: (2017)

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
por: Haselager, Marco V., et al.
Publicado: (2020)

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
por: Hofland, Tom, et al.
Publicado: (2019)

P595: DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Simon-Molas, Helga, et al.
Publicado: (2023)

Chronic lymphocytic leukemia presence impairs antigen-specific CD8(+) T-cell responses through epigenetic reprogramming towards short-lived effectors
por: Martens, Anne W. J., et al.
Publicado: (2023)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
por: Delgado, Raquel, et al.
Publicado: (2021)

Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling
por: van Attekum, MHA, et al.
Publicado: (2016)

CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis
por: van Attekum, Martijn H.A., et al.
Publicado: (2017)

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
por: Baliakas, Panagiotis, et al.
Publicado: (2022)

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
por: de Weerdt, Iris, et al.
Publicado: (2019)

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas
por: Martens, Anne W.J., et al.
Publicado: (2022)

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling
por: Hofland, Tom, et al.
Publicado: (2019)

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19
por: Jacobs, Chaja F., et al.
Publicado: (2021)

Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features
por: van der Straten, Lina, et al.
Publicado: (2021)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia
por: van Attekum, M H A, et al.
Publicado: (2017)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study
por: Leeksma, Alexander C., et al.
Publicado: (2020)

A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
por: Hoogeboom, Robbert, et al.
Publicado: (2013)

Telomere Dysfunction in Chronic Lymphocytic Leukemia
por: Jebaraj, Billy Michael Chelliah, et al.
Publicado: (2021)

Epigenetic evolution and lineage histories of chronic lymphocytic leukemia
por: Gaiti, Federico, et al.
Publicado: (2019)

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
por: Sharman, Jeffrey P., et al.
Publicado: (2022)

Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification
por: te Raa, G D, et al.
Publicado: (2015)

B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells
por: Minton, Annabel R., et al.
Publicado: (2022)

Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling
por: Singh, Simar Pal, et al.
Publicado: (2017)

Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia
por: Schubert, Maria, et al.
Publicado: (2018)

Epigenetic and genetic alterations and their influence on gene regulation in chronic lymphocytic leukemia
por: Huang, Di, et al.
Publicado: (2017)

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019
por: van der Straten, Lina, et al.
Publicado: (2023)

Phenotypic alteration of CD8(+) T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming
por: Wu, Jiazhu, et al.
Publicado: (2016)

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
por: Kater, Arnon P., et al.
Publicado: (2020)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients
por: Grimm, Christina, et al.
Publicado: (2022)

BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
por: Smith, Lindsay D., et al.
Publicado: (2019)

P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Haggenburg, Sabine, et al.
Publicado: (2023)

T-cell large granular lymphocyte leukemia: an Asian perspective
por: Kwong, Yok-Lam, et al.
Publicado: (2010)

Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
por: Griggio, Valentina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_afuvd7q997jgen9l410knkjn74